Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of complications from the virus. TVGN 489, the Company's investigational allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte (CTL) immunotherapy is developed using the ExacTcell platform. It is designed to fortify anti-SARS-CoV-2 immunity in these individuals and directly eliminate the virus. The CTLs are directed against the entire viral genome rather than single protein. Publication of positive POC/dose finding clinical trial data of TVGN 489 is available through Blood Advances:

Clinical Trial Key Findings:

• The treatment arm, which included high-risk patients and half of whom were immunocompromised, received a single infusion of TVGN 489.
• As a secondary end point, treated patients demonstrated faster and more consistent symptom resolution, compared to patients in the standard of care comparative arm.
• In the treatment arm, viral elimination reached >99% in all patients by day +14; no disease progression or Long COVID was observed in the treatment arm.
• TVGN 489 was well-tolerated at all four dose levels and did not impair endogenous immune responses.
• CTLs persisted in treated patients through six months of follow-up, an encouraging finding.
• TVGN 489 targets remain unaffected by mutations, including the current XFG SARS-CoV-2 variant.